Business Context and Reporting Period
Werewolf Therapeutics, Inc. filed this Form 8-K regarding matters voted on at its annual meeting of stockholders held May 24, 2024. The report was signed and filed on May 28, 2024. The company’s common stock trades on Nasdaq under the symbol HOWL.
Key Financial Metrics and Liquidity
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, or other financial operating metrics.
Material Changes
- Stockholders elected Michael Atkins, M.D., Luke Evnin, Ph.D., and Alon Lazarus, Ph.D. as Class III directors, each for a three-year term ending at the 2027 annual meeting.
- Stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
Voting Results
| Director | Votes For | Votes Withheld | Broker Non-Votes |
|---|---|---|---|
| Michael Atkins, M.D. | 31,566,857 | 19,721 | 5,145,182 |
| Luke Evnin, Ph.D. | 20,732,054 | 10,854,524 | 5,145,182 |
| Alon Lazarus, Ph.D. | 31,503,628 | 82,950 | 5,145,182 |
| Auditor Ratification | Votes |
|---|---|
| For | 36,686,933 |
| Against | 41,889 |
| Abstain | 2,938 |
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance, business outlook, risk updates, contingencies, or unusual financial items. It reports corporate governance actions only.
Investor Verification Points
- Verify the elected directors’ terms and their continued service through the 2027 annual meeting.
- Confirm Ernst & Young LLP’s appointment as auditor for fiscal 2024.
- Review the company’s periodic financial filings for operating results, cash runway, financing needs, and clinical-development updates, which are not included in this Form 8-K.